한글목차

세계 고형 종양 검사 시장의 미래는 병원, 제약 및 생명공학 기업, 위탁 연구기관, 학술 연구기관 등 다양한 시장에서의 기회로 인해 유망합니다. 세계 고형 종양 검사 시장 규모는 2025-2031년 3.5%의 CAGR로 2031년까지 약 1조 6,992억 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 보충제 및 스테로이드의 사용 증가, 흡연 및 음주와 같은 건강에 해로운 습관의 증가입니다.

• Lucintel의 예측에 따르면, 용도별로는 전 세계적으로 피부 종양 및 관련 질환의 발생률이 증가함에 따라 흑색종이 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.
• 최종 용도별로는 종양 및 만성질환 유병률 증가로 인해 병원이 가장 높은 성장세를 보일 것으로 예상됩니다.
• 지역별로는 북미가 강력한 헬스케어 인프라를 바탕으로 다양한 장기별 암 환자 증가로 인해 예측 기간 동안 가장 큰 성장을 보일 것으로 예상됩니다.

고형 종양 검사 시장의 전략적 성장 기회

고형 종양 검사 분야에서 주목받고 있는 기하학적 발전은 구성요소인 지오시스템의 기본 영역과 관련된 다양한 전략적 배제 옵션을 포함하고 있습니다. 특정 잠재적 가치의 개발은 진단 과정과 치료 결과를 개선하는 과제를 해결하는 데 도움이 될 수 있습니다.

• 개인맞춤의료의 도입 : 개인맞춤의료는 환자 개개인에게 적합한 고유한 검사를 설계할 수 있게 했습니다. 유전자를 종합적으로 조사함으로써 질병을 치료하고 환자의 건강 상태를 개선하는 데 더 효과적인 새로운 전략을 고안할 수 있습니다.
• 액체 생검 시장의 발전 : 비침습적 검사의 증가 추세로 인해 기업들은 액체 생검 시스템과 서비스를 강화할 수 있는 기회를 얻게 되었습니다. 이러한 추세는 환자를 편안하게 할 뿐만 아니라 치료 효과를 보다 적절하게 측정할 수 있게 해줍니다.
• 진단에 AI 기술 활용 : 고형 종양 검사에 AI를 적용하면 지능형 진단 솔루션 개발에 새로운 길을 열 수 있습니다. 이를 통해 방대한 정보를 체계적으로 선별하여 검사의 정확도를 높이고, 워크플로우의 효율성을 높이며, 진단에 이르는 시간을 단축할 수 있습니다.
• 조기 발견의 필요성 증가 : 암과 그 초기 증상에 대한 이해도가 높아짐에 따라 더 나은 검진 도구에 대한 필요성이 증가하고 있습니다. 따라서 더 나은 조기 발견 검사를 시장에 제공하기 위해 투자하는 주요 기업들은 업계에서 이러한 수요 증가로 인해 더 많은 이익을 얻을 수 있으며, 이는 곧 확대되는 고객층으로부터 더 큰 시장 점유율을 확보할 수 있는 기회로 이어질 것입니다.
• 선진 시장 공략 - 해외 사업 개척 : 신흥 시장, 특히 아시아와 아프리카 시장은 고형 종양 검사 비즈니스에 있어 훌륭한 길임이 입증될 것으로 예상됩니다. 이들 지역에 전략적으로 진출할 수 있는 기업들은 더 나은 진단 방법을 찾는 환자들이 늘어날 것으로 예상됩니다.

이러한 미래지향적인 성장 전략은 정밀의료, 기술, 혁신적인 진단 솔루션에 초점을 맞춰 고형 종양 검사 시장을 재정의하고 있습니다. 이러한 기회를 추구하는 업체들은 더 많은 시장 점유율을 확보하고 환자에게 제공되는 치료의 질을 향상시킬 수 있을 것으로 보입니다.

고형 종양 검사 시장의 촉진요인 및 과제

현재 시장 내 고형 종양 검사 시장과 마찬가지로, 향후 고형 종양 검사 시장도 여러 기술적, 경제적, 규제적 요인으로 인해 촉진요인으로 작용하거나 억제요인으로 작용할 수 있습니다. 환경이 계속 변화하는 가운데, 이해관계자들은 이러한 역학을 이해하는 것이 중요합니다.

고형 종양 검사 시장의 촉진요인은 다음과 같습니다:

1. 기술 발전 : 액체 생검, 유전체 프로파일링과 같은 검사 방법의 기술 혁신이 시장을 활성화하고 있습니다. 가장 중요한 것은 이러한 기술 혁신이 정확도를 높이고, 특정 치료법을 타겟팅하며, 다양한 치료법에 대한 환자의 접근성을 향상시킨다는 점입니다.

2. 암 발병률 증가 : 전 세계 암 발병률 증가로 인해 더 나은 검사 기술이 요구되고 있습니다. 조기 진단 서비스 및 적절한 치료법을 찾는 사람들이 증가함에 따라 고형 종양 검사 시장은 지속적으로 성장하고 있습니다.

3. 맞춤형 치료로의 전환 : 정밀의료에 대한 관심이 높아지면서 고형 종양 검사의 패러다임이 바뀌고 있습니다. 환자와 의료진은 보다 효과적인 표적 치료로 치료할 수 있는 특정 돌연변이를 밝혀낼 수 있는 검사를 점점 더 많이 요구하고 있습니다.

4. 정부 정책 장려 : 규제 당국은 혁신적인 검사 아이디어를 장려하고 새로운 기기의 시장 출시 기간을 단축하고 있습니다. 이러한 분위기는 연구 개발 활동의 수행을 촉진하고, 궁극적으로 최신의 첨단 진단 장비의 공급을 증가시킵니다.

5. 의료 재정 성장 : 고형 종양 검사 시장의 성장은 공공 및 민간 기관의 의료 인프라 및 생명공학에 대한 투자에 의해 촉진될 것입니다. 자금 조달의 개선은 정교한 진단 접근법의 창출과 활용을 촉진할 것입니다.

고형 종양 검사 시장의 과제는 다음과 같습니다:

1. 규제 장애물 : 규제 당국의 승인을 받는 경우도 있지만, 새로운 기술을 승인받는 것은 쉽지 않습니다. 혁신적인 기업들은 최첨단 솔루션을 출시하는 데 어려움을 겪으며, 이는 경쟁에 악영향을 미칠 수 있습니다.

2. 시장 세분화 : 이차성 악성종양 검사 시장은 통합성이 낮고, 많은 이해관계자들이 서로 다른 서비스를 제공하고 있습니다. 이러한 파편화는 의료진과 환자의 혼란을 초래하고, 결과적으로 검사에 대한 잘못된 선택을 초래할 수 있습니다.

고형 종양 검사 시장의 성장을 뒷받침하는 요인과 성장을 저해하는 요인의 균형은 매우 분명합니다. 환자 치료를 개선하고 암 진단의 효과적이고 진보적인 발전을 촉진하기 위해서는 이용 가능한 기술 개발을 활용하고 과제를 해결하는 것이 필수적입니다.

목차

제1장 주요 요약

제2장 세계의 고형 종양 검사 시장 : 시장 역학

• 소개, 배경, 분류
• 공급망
• 업계 성장 촉진요인과 과제

제3장 시장 동향과 예측 분석(2019-2031년)

• 거시경제 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 고형 종양 검사 시장 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 고형 종양 검사 시장 : 유형별
  • 유전자 검사
  • 기존 검사
• 세계의 고형 종양 검사 시장 : 용도별
  • 전립선
  • 흉부
  • 대장
  • 자궁내막
  • 폐
  • 악성 흑색종
  • 기타
• 세계의 고형 종양 검사 시장 : 최종 용도별
  • 병원
  • 제약·바이오테크놀러지 기업
  • 수탁연구기관
  • 학술연구기관

제4장 시장 동향과 예측 분석 : 지역별(2019-2031년)

• 지역별 고형 종양 검사 시장
• 북미의 고형 종양 검사 시장
• 유럽의 고형 종양 검사 시장
• 아시아태평양의 고형 종양 검사 시장
• 기타 지역의 고형 종양 검사 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 세계의 고형 종양 검사 시장 성장 기회 : 유형별
  • 세계의 고형 종양 검사 시장 성장 기회 : 용도별
  • 세계의 고형 종양 검사 시장 성장 기회 : 최종 용도별
  • 세계의 고형 종양 검사 시장 성장 기회 : 지역별
• 세계의 고형 종양 검사 시장의 최신 동향
• 전략 분석
  • 신제품 개발
  • 세계의 고형 종양 검사 시장 생산능력 확대
  • 세계의 고형 종양 검사 시장 합병, 인수, 합작투자
  • 인증과 라이선싱

제7장 주요 기업 개요

• Agilent Technologies
• MYRIAD GENETICS
• Biocare Medical
• ILLUMINA
• F. Hoffmann-La Roche
• QIAGEN
• MedGenome Labs
• Thermo Fisher Scientific
• Abbott Laboratories
• QUEST DIAGNOSTICS

영문목차

The future of the global solid tumor testing market looks promising with opportunities in the hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions markets. The global solid tumor testing market is expected to reach an estimated $1699.2 billion by 2031 with a CAGR of 3.5% from 2025 to 2031. The major drivers for this market are the increase in the utilization of supplements and steroids and an increase in unhealthy habits, such as smoking and alcohol consumption.

• Lucintel forecasts that, within the application category, melanoma is expected to witness the highest growth over the forecast period due to the growing incidence of skin tumors and related conditions globally.
• Within the end use category, the hospital is expected to witness the highest growth due to the rising incidence of tumors and chronic diseases.
• In terms of regions, North America is expected to witness the largest growth over the forecast period due to a rise in various organ-specific cancer cases, supported by a robust healthcare infrastructure.

Gain Valuable Insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Solid Tumor Testing Market

The solid tumor testing market is being shaped by emerging trends in the field that are changing the aspects of diagnostics and treatment methods. These trends are marked by differences in technologies, changes in the healthcare system, and a shift in focus toward the patient.

• Liquid Biopsy Technology: Liquid biopsy technology includes the examination of liquid samples from patients to identify solid tumors by analyzing circulating tumor DNA (ctDNA). Monitoring tumor behavior and its changes can help improve the personalization of treatment and decrease the number of invasive procedures used.
• Genomic Profiling: Comprehensive genomic profiling is becoming an essential component of cancer management as it helps in the detection of mutations in different tumors. In this context, agents that promote the creation of drugs that target specific molecules are likely to be beneficial to patients, especially in cases of cancer types with metastatic potential.
• Integration of AI and Machine Learning: The use of AI and machine learning in performing solid tumor tests improves the accuracy and speed of diagnosis. Such technologies analyze vast amounts of data to identify potential trends and forecast the outcomes of treatments, assisting doctors in formulating appropriate treatment measures.
• Increased Focus on Early Detection: There is an increasing focus on the early detection of solid tumors, as this significantly increases the chances of successfully treating affected individuals. There is a need to develop strategies for providing regular check-ups and advanced diagnostic approaches to ensure that cancers are detected at an earlier stage when they are most treatable.
• Regulatory Attitude Towards Technology: Regulatory authorities have started to recognize and promote more innovative and novel diagnostic solutions, which accelerate the approval of new technologies and streamline the approval systems. This scenario is supportive of both the establishment and practice of research and development, which will, in turn, increase the chances of these sophisticated testing procedures becoming commonplace in routine use.

These new trends are revitalizing the solid tumor testing segment of the market by strengthening the capabilities of diagnostics, encouraging targeted approaches, and improving the healthcare provided. With the rapid rate of technological changes, it will not be surprising to find that all these trends will be integrated in further tackling the problems associated with cancer.

Recent Developments in the Solid Tumor Testing Market

The market for solid tumor testing has its share of developments that stand out with improvements in the accuracy and management of treatment. Such trends are all towards an increase in personalized medicine and a demand for advancements in treatment technology concerning cancer.

• Liquid Biopsy Advancements: Recent developments in the liquid biopsy field have allowed for the non-invasive detection of solid tumors via the analysis of ctDNA bioassays. This development significantly augments the surveillance of patients and any changes that may be made in the course of treatment, showing how the tumor is behaving as well as the effects of the treatment given.
• Genomic Profiling Approvals: The endorsement of policies for the approval of diverse molecular profiling tests by health regulators has made access to selected therapies easier. Using these tests, oncologists can isolate certain mutations that, in turn, lead to tailored surgical intervention plans that improve positive outcomes and reduce negative effects in patients.
• AI-Driven Diagnostics: The use of artificial intelligence systems in testing solid tumors is changing the way things are done in the industry. AI techniques are better equipped to evaluate multifaceted data compared to traditional approaches, thereby making diagnosis and treatment processes faster by providing more informed treatment options for patients.
• Collaborative Research Initiatives: Collaboration between universities and biotech firms has fostered the improvement of cancer diagnostic techniques. International collaboration, for example, supports technology development and improves testing strategies so that advanced technologies reach clinicians more quickly.
• Global Standardization Efforts: The global standardization movement of solid tumor biological diagnostic testing procedures is gaining the momentum it deserves. It seeks the harmonization of diagnostic testing strategies so that uniformity and reproducibility of particular tests are achieved, which will, in turn, improve the quality of care for patients worldwide.

These key advancements have benefited the solid tumor testing market through better diagnosis, extended treatment alternatives, and effective patient management. It is clear that emphasizing the challenges and possible solutions brings about more opportunities for future developments in this field.

Strategic Growth Opportunities for Solid Tumor Testing Market

The geometrical progression that attracts attention in the area of solid tumor testing encompasses diverse strategic exclusion options related to the component geosystems basis territory diversified. The development of specific potential values helps address the challenges that enhance the diagnosis processes and treatment outcomes.

• Introduction of Personalized Medicine: Personalized medicine has made it possible to design unique tests that are appropriate for an individual patient. A comprehensive investigation of genes can help devise new strategies that are more effective in treating diseases and improving the health status of patients.
• Advancing the Liquid Biopsy Market: Looking at the growing trend of non-invasive testing, companies have an opportunity to enhance their liquid biopsy systems and services. This trend helps not only to make patients comfortable but also allows better measurement of treatment response.
• Using AI Technology for Diagnostics: The application of AI in solid tumor testing creates new pathways for the development of intelligent diagnostic solutions. These can sift through a massive amount of information systematically to improve the accuracy of tests, increase workflow efficiency, and reduce the time taken to arrive at a diagnosis.
• There is a growing need for early detection: Increased understanding of cancer and its early symptoms has necessitated the need for better screening tools. Thus, companies that invest in bringing forth better early detection tests for the market can gain more from this growing need in the industry, which, in turn, leads to a larger market share from the expanding clientele.
• Developed Markets Target-Expansion of Overseas Operations: Emerging markets, especially in Asia and Africa, will prove to be great avenues for the solid tumor testing business. Companies that can strategically enter these areas will find an increasing number of patients seeking better ways to diagnose their diseases.

These forward-looking growth strategies are redefining the solid tumor testing market by focusing on precision medicine, technology, and novel diagnostic solutions. Providers who pursue these opportunities will capture more market share and enhance the quality of care provided to patients.

Solid Tumor Testing Market Driver and Challenges

Similar to solid tumor testing within the market, the upcoming solid tumor testing market also suffers from several technological, economic, and regulatory factors that act as both enablers and inhibitors. Understanding these dynamics is important for stakeholders as the environment continues to change.

The factors responsible for driving the solid tumor testing market include:

1. Technological Advancements: Technological innovations in testing methods, including liquid biopsies and genomic profiling, are fueling the market. Most importantly, these innovations increase accuracy, target specific therapies, and improve patient access to diverse treatments.

2. Increasing Cancer Incidence: The increasing global burden of cancer is demanding better testing techniques. As more people request early diagnosis services and suitable therapies, the market for solid tumor testing continues to grow.

3. Shift Towards Individualized Treatment: There is a paradigm shift in solid tumor testing driven by an increasing focus on precision medicine. More and more, patients and providers are looking for tests that can reveal particular mutations that can then be treated with more effective targeted therapies.

4. Government Policy Encouragement: Regulatory authorities are promoting innovative testing ideas and shortening the duration of introducing new devices to the market. This atmosphere favors conducting R&D activities, which ultimately results in an increased supply of modern and advanced diagnostic equipment.

5. Growth in Healthcare Financing: Growth in the solid tumor testing market is fueled by investment in healthcare infrastructure and biotechnology by public and private institutions. Improved funding facilitates the creation and use of sophisticated diagnostic approaches.

Challenges in the solid tumor testing market include:

1. Regulatory Hurdles: Although regulatory endorsement is acquired in some cases, it is not straightforward to gain approval for new technology. Innovative companies experience problems launching their cutting-edge solutions, which negatively impacts competition.

2. Market Fragmentation: The market for testing malignant secondary tumors is poorly consolidated, and many stakeholders offer different services. This fragmentation leads to confusion among medical practitioners and patients, resulting in poor choices regarding testing.

The balance of factors that support the development and barriers to the expansion of the solid tumor testing market is quite evident. It is essential to utilize available technological developments and address challenges to improve patient care and foster the effective and progressive development of cancer diagnostics.

List of Solid Tumor Testing Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies solid tumor testing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the solid tumor testing companies profiled in this report include-

• Agilent Technologies
• MYRIAD GENETICS
• Biocare Medical
• ILLUMINA
• F. Hoffmann-La Roche
• QIAGEN
• MedGenome Labs
• Thermo Fisher Scientific
• Abbott Laboratories
• QUEST DIAGNOSTICS

Solid Tumor Testing by Segment

The study includes a forecast for the global solid tumor testing market by type, application, end use, and region.

Solid Tumor Testing Market by Type [Analysis by Value from 2019 to 2031]:

• Genetic Testing
• Conventional Testing

Solid Tumor Testing Market by Application [Analysis by Value from 2019 to 2031]:

• Prostate
• Breast
• Colorectal
• Endometrial
• Lung
• Melanoma
• Others

Solid Tumor Testing Market by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic Research Institutions

Solid Tumor Testing Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Solid Tumor Testing Market

The solid tumor testing market is undergoing dramatic changes in some countries primarily due to technological breakthroughs and increases in healthcare expenditure and focus on personalized medicine. This is particularly true for the United States, China, Germany, India, and Japan, each of which is progressing in specific areas to enhance diagnostic devices and therapeutic approaches.

• USA: There is rapid development of liquid biopsy technologies, which revolutionize the way cancer is diagnosed through non-invasive methods for solid tumors that do not require invasive surgery. With the increasing number of approvals for genomic profiling tests, it is possible to develop targeted therapies. Apart from this, partnerships between biotech companies and healthcare providers enhance diagnostics.
• China: Such development in China regarding the solid tumor market is observed primarily because of the influx of public funds in the field of biotechnology, including healthcare. An increase in inhibitory activity in management, including management of precision medicine programs, is witnessed with a growing volume in the utilization of complicated genomic tests. No affordable management has grown this change for focal management specifically at centers, as they reduce the rate of delay and assist in developing better management strategies.
• Germany: Germany's solid tumor testing market is supported by impressive research activity and collaboration between research institutes and businesses. The country is moving toward next-generation sequencing (NGS) technologies, which further improve diagnostic accuracy and support the implementation of specific treatments. Innovative testing approaches are also being accepted, as improvements in regulatory guidance encourage the development of new diagnostic methods.
• India: The solid tumor testing market is fueled by the growing incidence of cancer among the population in India. Low-cost genomic diagnostic tests, developed for the majority of the population by emerging companies, promote early diagnosis and treatment personalization. Improvements in cancer diagnostics are also aided by increased public awareness and government policies.
• Japan: Japan is expanding its solid tumor testing market by employing new imaging methodologies along with NGS in the field of solid tumors. The government is encouraging doctors to adopt precision medicine concepts, resulting in more mechanisms for treating cancers. Marketing drafts created in cooperation with Japanese companies and foreign companies have expanded the supply of new diagnostic methods.

Features of the Global Solid Tumor Testing Market

Market Size Estimates: Solid tumor testing market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Solid tumor testing market size by type, application, end use, and region in terms of value ($B).

Regional Analysis: Solid tumor testing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, application, end use, and regions for the solid tumor testing market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the solid tumor testing market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the solid tumor testing market by type (genetic testing and conventional testing), application (prostate, breast, colorectal, endometrial, lung, melanoma, and others), end use (hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Solid Tumor Testing Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Solid Tumor Testing Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Solid Tumor Testing Market by Type
  • 3.3.1: Genetic Testing
  • 3.3.2: Conventional Testing
• 3.4: Global Solid Tumor Testing Market by Application
  • 3.4.1: Prostate
  • 3.4.2: Breast
  • 3.4.3: Colorectal
  • 3.4.4: Endometrial
  • 3.4.5: Lung
  • 3.4.6: Melanoma
  • 3.4.7: Others
• 3.5: Global Solid Tumor Testing Market by End Use
  • 3.5.1: Hospitals
  • 3.5.2: Pharmaceutical & Biotechnology Companies
  • 3.5.3: Contract Research Organizations
  • 3.5.4: Academic Research Institutions

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Solid Tumor Testing Market by Region
• 4.2: North American Solid Tumor Testing Market
  • 4.2.1: North American Market by Application: Prostate, Breast, Colorectal, Endometrial, Lung, Melanoma, and Others
  • 4.2.2: North American Market by End Use: Hospitals, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Academic Research Institutions
• 4.3: European Solid Tumor Testing Market
  • 4.3.1: European Market by Application: Prostate, Breast, Colorectal, Endometrial, Lung, Melanoma, and Others
  • 4.3.2: European Market by End Use: Hospitals, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Academic Research Institutions
• 4.4: APAC Solid Tumor Testing Market
  • 4.4.1: APAC Market by Application: Prostate, Breast, Colorectal, Endometrial, Lung, Melanoma, and Others
  • 4.4.2: APAC Market by End Use: Hospitals, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Academic Research Institutions
• 4.5: ROW Solid Tumor Testing Market
  • 4.5.1: ROW Market by Application: Prostate, Breast, Colorectal, Endometrial, Lung, Melanoma, and Others
  • 4.5.2: ROW Market by End Use: Hospitals, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Academic Research Institutions

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Solid Tumor Testing Market by Type
  • 6.1.2: Growth Opportunities for the Global Solid Tumor Testing Market by Application
  • 6.1.3: Growth Opportunities for the Global Solid Tumor Testing Market by End Use
  • 6.1.4: Growth Opportunities for the Global Solid Tumor Testing Market by Region
• 6.2: Emerging Trends in the Global Solid Tumor Testing Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Solid Tumor Testing Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Solid Tumor Testing Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Agilent Technologies
• 7.2: MYRIAD GENETICS
• 7.3: Biocare Medical
• 7.4: ILLUMINA
• 7.5: F. Hoffmann-La Roche
• 7.6: QIAGEN
• 7.7: MedGenome Labs
• 7.8: Thermo Fisher Scientific
• 7.9: Abbott Laboratories
• 7.10: QUEST DIAGNOSTICS